Search Results - "Broijl, A."

Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease by van Andel, H, Kocemba, K A, de Haan-Kramer, A, Mellink, C H, Piwowar, M, Broijl, A, van Duin, M, Sonneveld, P, Maurice, M M, Kersten, M J, Spaargaren, M, Pals, S T

“…Deletion or mutation of the gene encoding the deubiquitinating enzyme CYLD is a common genomic aberration in multiple myeloma (MM). However, the functional…”
Get full text

P37 MULTIPLE MYELOMA MONITORING FROM ARCHIVED SERUM PROTEIN ELECTROPHORESIS GELS BY MASS SPECTROMETRY AND DE NOVO SEQUENCING by Noori, S., Zajec, M., Russcher, H., Tintu, A.N., Broijl, A., Jacobs, J.F.M., Luider, T.M., Rijke, Y.B., vanDuijn, M.M.

Get full text

P24: EXPERT PERSPECTIVES OF UNMET NEED IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE LENALIDOMIDE‐SPARING REGIMENS IN EUROPE by Mateos, M, Leleu, X, Zamagni, E, Delforge, M, Bringhen, S, Broijl, A, Rubia, J, Shaw, A, Brescianini, A, Gonzalez‐McQuire, S, Patel, S, Moreau, P

Get full text

B01: STROMAL CELL‐NEUTROPHIL INTERACTIONS PROMOTE A PRO‐TUMOR ENVIRONMENT IN MULTIPLE MYELOMA by Jong, M, Fokkema, C, Heusden, T, Papazian, N, Tahri, S, Kellermayer, Z, Vermeulen, P, Duin, M, Woestijne, P, Broijl, A, Sonneveld, P, Cupedo, T

Get full text

P23 EMAGINE/CARTITUDE‐6: A RANDOMIZED PHASE 3 STUDY OF DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN TRANSPLANT‐ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA by Broijl, A., San‐Miguel, J., Suzuki, K., Krishnan, A., Donk, N., Cook, G., Jakubowiak, A., Madduri, D., Afifi, S., Stevens, A., Schecter, J., Deraedt, W., Kuppens, S., Mistry, P., Pacaud, L., Boccadoro, M., Gay, F., Mina, R., Rasche, L., Moreau, P., Mateos, M., Einsele, H., Sonneveld, P.

Get full text

B05 PLASMA CELL LEUKEMIA‐LIKE STATUS HAS INDEPENDENT PROGNOSTIC VALUE IN THE CONTEXT OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM by Hofste op Bruinink, D., Kuiper, R., Duin, M., Cupedo, T., Velden, V., Hoogenboezem, R., Holt, B., Beverloo, B., Valent, E., Vermeulen, M., D'Agostino, M., Gay, F., Broijl, A., Avet‐Loiseau, H., Munshi, N., Musto, P., Moreau, P., Zweegman, S., Donk, N., Sonneveld, P.

Get full text

P1463: PHASE I DOSE ESCALATION OF LAVA‐051, A NOVEL BISPECIFIC GAMMA‐DELTA T‐CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES by Broijl, A., Donk, N., Bosch, F., Mateos, M. V., Rodriguez‐Otero, P., Tucci, A., Ghia, P., Adang, A., Parren, P., Tuinhof, I., Umarale, S., Winograd, B., Vliet, H., Kater, A.

Get full text

The Risk Classification based on Gene Expression Profiling: a Tool for Prediction of High- and Low-risk Multiple Myeloma across International Trials by Sonneveld, P, Kuiper, R, Broijl, A, van Duin, M

Get full text

B07 HIGH EXPRESSION OF NUCLEAR CEREBLON IS ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMIDS by Wester, R., van Duin, M., Lam, K.H., Couto, S.S., Ren, Y., Wang, M., Cupedo, T., van der Holt, B., Beverloo, H.B., Nigg, A.L., Thakurta, A., Waage, A.A., Zweegman, S., Broijl, A., Sonneveld, P.

Get full text

Multiple Myeloma Subtyping That Associates Normal B-Cell Subset Phenotypes, do Correlate to Disease Stage and Prognosis - Indication of Reversible Phenotypic Plasticity as a Hallmark by Johnsen, H.E, Bødker, J.S, Schmitz, A, Falgreen, S, Perez-Andres, M, Samur, M.K, Davies, F, Pawlyn, C, Kaiser, M, Johnson, D, Bertsch, U, Broijl, A, van Duin, M, Shah, R, Kjeldsen, M.K, Bergkvist, K.S, Bilgrau, A.E, Johansen, P, El-Galaly, T.C, Samworth, R, Sonneveld, P, Goldschmidt, H, Morgan, G.J, Orfao, A, Munshi, N, Dybkær, K, Bøgsted, M

Get full text

Treatment of relapsed and refractory multiple myeloma by Sonneveld, Pieter, Broijl, Annemiek

Get full text

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial by Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, Le, Salwender, H J, Sonneveld, P

“…The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial…”
Get full text

Chemotherapy-induced peripheral neuropathies in hematological malignancies by Jongen, Joost Louis Marie, Broijl, Annemiek, Sonneveld, Pieter

“…Recent developments in the treatment of hematological malignancies, especially with the advent of proteasome inhibitors and immunomodulatory drugs in plasma…”
Get full text

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma by Nijhof, Inger S., Franssen, Laurens E., Levin, Mark-David, Bos, Gerard M.J., Broijl, Annemiek, Klein, Saskia K., Koene, Harry R., Bloem, Andries C., Beeker, Aart, Faber, Laura M., van der Spek, Ellen, Ypma, Paula F., Raymakers, Reinier, van Spronsen, Dick-Johan, Westerweel, Peter E., Oostvogels, Rimke, van Velzen, Jeroen, van Kessel, Berris, Mutis, Tuna, Sonneveld, Pieter, Zweegman, Sonja, Lokhorst, Henk M., van de Donk, Niels W.C.J.

“…The prognosis of multiple myeloma (MM) patients who become refractory to lenalidomide and bortezomib is very poor, indicating the need for new therapeutic…”
Get full text

B07 HIGH EXPRESSION OF NUCLEAR CEREBLON IS ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMIDS by Wester, R., Duin, M., Lam, K.H., Couto, S.S., Ren, Y., Wang, M., Cupedo, T., Holt, B., Beverloo, H.B., Nigg, A.L., Thakurta, A., Waage, A.A., Zweegman, S., Broijl, A., Sonneveld, P.

Get full text

PS1385 THE IMPACT OF A PRIOR MALIGNANCY ON THE DEVELOPMENT OF A SUBSEQUENT MALIGNANCY IN MULTIPLE MYELOMA REVISITED: A COMPETING RISK ANALYSES by Brink, M., Minnema, M.C., Visser, O., Broijl, A., Donk, N.W., Sonneveld, P., Zweegman, S., Dinmohamed, A.G.

“…Background: Jonsdottir et al. (Blood Adv. 2017) recently suggested that, among the population of Sweden, a prior malignancy diagnosis (PMD) before the onset of…”
Get full text

PS1374 PROGNOSIS IN ELDERLY MULTIPLE MYELOMA PATIENTS IN THE HOVON‐87/NMSG‐18 STUDY BASED ON REVISED ISS AND SKY92‐ISS by Kuiper, R., Broijl, A., Vliet, M.H., Duin, M., Levin, M.‐D., Beers, E.H., Holt, B., Visser, H., Hansson, M., Velden, A.W.G., Dumee, B., Vermeulen, M., Koenders, J., Beverloo, H.B., Stevens‐Kroef, M., Sonneveld, P., Waage, A., Zweegman, S.

“…Background: The incidence of multiple myeloma (MM) increases with age with a median at diagnosis of 69 years. Patients older than 65 years old are often…”
Get full text

PS1377 IMPROVEMENT IN HEALTH‐RELATED QUALITY OF LIFE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT‐ELIGIBLE PATIENTS TREATED WITH DARATUMUMAB, BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE: CASSIOPEIA STUDY by Roussel, M., Moreau, P., Attal, M., Eisenmann, J.‐C., Laribi, K., Jaccard, A., Dib, M., Slama, B., Chaleteix, C., Dorvaux, V., Royer, B., Frenzel, L., Zweegman, S., Klein, S.K., Broijl, A., Jie, K.‐S., Araujo, C., Vanquickelberghe, V., Boer, C., Kampfenkel, T., Vermeulen, J., McKay, C., Gries, K.S., Trudeau, J., Sonneveld, P.

“…Background: CASSIOPEIA, a phase 3 trial of patients (pts) with newly diagnosed multiple myeloma (NDMM) eligible for autologous stem cell transplant (ASCT),…”
Get full text

S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D‐VTD) VERSUS VTD IN TRANSPLANT‐ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS by Moreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., Corre, J., Delforge, M., Dejoie, T., Doyen, C., Facon, T., Sonntag, C., Garderet, L., Jie, K.‐S., Karlin, L., Kuhnowski, F., Lambert, J., Leleu, X., Lenain, P., Macro, M., Orsini‐Piocelle, F., Perrot, A., Stoppa, A.‐M., Donk, N. W., Wuilleme, S., Zweegman, S., Kolb, B., Touzeau, C., Roussel, M., Tiab, M., Marolleau, J.‐P., Meuleman, N., Vekemans, M.‐C., Westerman, M., Klein, S. K., Levin, M.‐D., Escoffre‐Barbe, M., Eveillard, J.‐R., Garidi, R., Ahmadi, T., Zhuang, S., Chiu, C., Pei, L., Vanquickelberghe, V., Boer, C., Smith, E., Deraedt, W., Kampfenkel, T., Schecter, J., Vermeulen, J., Avet‐Loiseau, H., Sonneveld, P.

“…Background: VTd is a standard of care for transplant‐eligible newly diagnosed multiple myeloma (NDMM) patients. Daratumumab (DARA), a CD38 mAb, significantly…”
Get full text

S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS by Moreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., Corre, J., Delforge, M., Dejoie, T., Doyen, C., Facon, T., Sonntag, C., Garderet, L., Jie, K.-S., Karlin, L., Kuhnowski, F., Lambert, J., Leleu, X., Lenain, P., Macro, M., Orsini-Piocelle, F., Perrot, A., Stoppa, A.-M., van de Donk, N. W., Wuilleme, S., Zweegman, S., Kolb, B., Touzeau, C., Roussel, M., Tiab, M., Marolleau, J.-P., Meuleman, N., Vekemans, M.-C., Westerman, M., Klein, S. K., Levin, M.-D., Escoffre-Barbe, M., Eveillard, J.-R., Garidi, R., Ahmadi, T., Zhuang, S., Chiu, C., Pei, L., Vanquickelberghe, V., de Boer, C., Smith, E., Deraedt, W., Kampfenkel, T., Schecter, J., Vermeulen, J., Avet-Loiseau, H., Sonneveld, P.

Get full text